
PLx Pharma (PLXP) Earnings Dates & Reports
PLx Pharma (PLXP) Most Recent Earnings
Report Date
Period EndingQ3 2022
Est. EPS-$0.44
Actual EPS-$0.37
EarningsBeat
PLx Pharma (PLXP) Earnings
View the latest PLx Pharma (PLXP) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in PLx Pharma (PLXP)
Order type
Buy in
Order amount
Est. shares
0 shares
PLx Pharma (PLXP) Earnings per Share (EPS) History
Signup for full accessBrowse free
PLx Pharma (PLXP) Latest Earnings
The value each PLXP share was expected to gain vs. the value each share gained.
PLx Pharma (PLXP) reported its most recent earnings on for Q3 2022, posting earnings per share (EPS) of -$0.37. This exceeded analysts' expectations of -$0.44 by 15.91%, marking a Beat.
For comparison, PLx Pharma reported EPS of -$0.37 in the same quarter last year.
The company is expected to announce its next earnings report on , with analysts projecting an EPS of $0.
PLx Pharma (PLXP) Earnings History
PLx Pharma (PLXP) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the PLx Pharma’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
| Report date | Price 1D before | Price 1D after | Change |
|---|---|---|---|
| — | — | — | |
| — | — | — | |
| — | — | — | |
| — | — | — |
PLx Pharma (PLXP) Earnings FAQs
PLx Pharma (PLXP) last reported earnings on Nov 11, 2022 for Q3 2022, posting an EPS of -$0.37, which Beat the estimate of -$0.44 by 15.91%.
For Q3 2022, PLx Pharma (PLXP) reported an EPS of -$0.37, exceeding analysts' estimate of -$0.44 by 15.91%.
For Q3 2022, PLx Pharma (PLXP) Beat expectations with an actual EPS of -$0.37 vs. an estimated EPS of -$0.44.
Following the last earnings report on Nov 11, 2022, PLx Pharma (PLXP)'s stock price moved — from — to —.
The next PLx Pharma (PLXP) earnings call is scheduled for Nov. 10, 2022, where executives will discuss financial results and outlook.